Effect of Auristatin PHE on Microtubule Integrity and Nuclear Localization in Cryptococcus Neoformans

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2002 Nov 19

PMID 12435680

Citations 6

Authors

Tanja Woyke

Robert W Roberson

George R Pettit

Gunther Winkelmann

Robin K Pettit

Affiliations

Soon will be listed here.

Abstract

The mechanism of action of the fungicidal peptide auristatin PHE was investigated in Cryptococcus neoformans. Since auristatin PHE causes budding arrest in C. neoformans (T. Woyke, G. R. Pettit, G. Winkelmann, and R. K. Pettit, Antimicrob. Agents Chemother. 45:3580-3584, 2001), microtubule integrity and nuclear localization in auristatin PHE-treated cells were examined. Iterative deconvolution in conjunction with an optimized C. neoformans microtubule immunolabeling procedure enabled detailed visualization of the microtubule cytoskeleton in auristatin PHE-treated C. neoformans. The effect of auristatin PHE on C. neoformans microtubule organization was compared with that of the tubulin-binding agent nocodazole. Both drugs produced complete disruption first of cytoplasmic and then of spindle microtubules in a time- and concentration-dependent manner. Sub-MICs of auristatin PHE caused complete microtubule disruption within 4.5 h, while 1.5 times the nocodazole MIC was required for the same effect. For both drugs, disruption of microtubules was accompanied by blockage of nuclear migration and of nuclear and cellular division, resulting in cells arrested in a uninucleate, large-budded stage. Nocodazole and the linear peptide auristatin PHE are remarkably different in structure and spectrum of activity, yet on the cellular level, they have similar effects.

Citing Articles

Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.

Tan L, Salleh N Molecules. 2024; 29(22).

PMID: 39598696 PMC: 11596561. DOI: 10.3390/molecules29225307.

Polo-like kinase Cdc5 regulates Spc72 recruitment to spindle pole body in the methylotrophic yeast .

Maekawa H, Neuner A, Ruthnick D, Schiebel E, Pereira G, Kaneko Y Elife. 2017; 6.

PMID: 28853395 PMC: 5626484. DOI: 10.7554/eLife.24340.

Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans.

Bouklas T, Fries B Fungal Genet Biol. 2014; 78:59-64.

PMID: 25307541 PMC: 4395511. DOI: 10.1016/j.fgb.2014.10.004.

Antineoplastic agents. 590. X-ray crystal structure of dolastatin 16 and syntheses of the dolamethylleuine and dolaphenvaline units.

Pettit G, Smith T, Xu J, Herald D, Flahive E, Anderson C J Nat Prod. 2011; 74(5):1003-8.

PMID: 21539315 PMC: 3111978. DOI: 10.1021/np100877h.

The capsule of the fungal pathogen Cryptococcus neoformans.

Zaragoza O, Rodrigues M, De Jesus M, Frases S, Dadachova E, Casadevall A Adv Appl Microbiol. 2009; 68:133-216.

PMID: 19426855 PMC: 2739887. DOI: 10.1016/S0065-2164(09)01204-0.

References

Jung M, Wilder I, Oakley B . Amino acid alterations in the benA (beta-tubulin) gene of Aspergillus nidulans that confer benomyl resistance. Cell Motil Cytoskeleton. 1992; 22(3):170-4. DOI: 10.1002/cm.970220304. View

Fujimura M, Oeda K, Inoue H, Kato T . A single amino-acid substitution in the beta-tubulin gene of Neurospora confers both carbendazim resistance and diethofencarb sensitivity. Curr Genet. 1992; 21(4-5):399-404. DOI: 10.1007/BF00351701. View

Umesono K, Toda T, Hayashi S, Yanagida M . Cell division cycle genes nda2 and nda3 of the fission yeast Schizosaccharomyces pombe control microtubular organization and sensitivity to anti-mitotic benzimidazole compounds. J Mol Biol. 1983; 168(2):271-84. DOI: 10.1016/s0022-2836(83)80018-7. View

Hoebeke J, Van Nijen G, De Brabander M . Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. Biochem Biophys Res Commun. 1976; 69(2):319-24. DOI: 10.1016/0006-291x(76)90524-6. View

McCully E, Robinow C . Mitosis in heterobasidiomycetous yeasts. I. Leucosporidium scottii (Candida Scottii). J Cell Sci. 1972; 10(3):857-81. DOI: 10.1242/jcs.10.3.857. View

de Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk J, van Boxtel C, van Ketel R . Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS. 1992; 6(2):185-90. DOI: 10.1097/00002030-199202000-00007. View

Toda T, Umesono K, Hirata A, Yanagida M . Cold-sensitive nuclear division arrest mutants of the fission yeast Schizosaccharomyces pombe. J Mol Biol. 1983; 168(2):251-70. DOI: 10.1016/s0022-2836(83)80017-5. View

Kilmartin J . Purification of yeast tubulin by self-assembly in vitro. Biochemistry. 1981; 20(12):3629-33. DOI: 10.1021/bi00515a050. View

Kelly S, Lamb D, Taylor M, Corran A, Baldwin B, Powderly W . Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett. 1994; 122(1-2):39-42. DOI: 10.1111/j.1574-6968.1994.tb07140.x. View

10.

Pettit G, Srirangam J, Barkoczy J, Williams M, Boyd M, Hamel E . Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des. 1998; 13(4):243-77. View

11.

Hogan L, Klein B, Levitz S . Virulence factors of medically important fungi. Clin Microbiol Rev. 1996; 9(4):469-88. PMC: 172905. DOI: 10.1128/CMR.9.4.469. View

12.

Pettit R, Pettit G, Hazen K . Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans. Antimicrob Agents Chemother. 1998; 42(11):2961-5. PMC: 105973. DOI: 10.1128/AAC.42.11.2961. View

13.

McNally J, Karpova T, Cooper J, Conchello J . Three-dimensional imaging by deconvolution microscopy. Methods. 1999; 19(3):373-85. DOI: 10.1006/meth.1999.0873. View

14.

Pringle J, Adams A, Drubin D, Haarer B . Immunofluorescence methods for yeast. Methods Enzymol. 1991; 194:565-602. DOI: 10.1016/0076-6879(91)94043-c. View

15.

Oakley B, Morris N . A beta-tubulin mutation in Aspergillus nidulans that blocks microtubule function without blocking assembly. Cell. 1981; 24(3):837-45. DOI: 10.1016/0092-8674(81)90109-4. View

16.

van der Horst C, Saag M, Cloud G, Hamill R, Graybill J, Sobel J . Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997; 337(1):15-21. DOI: 10.1056/NEJM199707033370103. View

17.

Joseph-Horne T, Hollomon D, Loeffler R, Kelly S . Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother. 1995; 39(7):1526-9. PMC: 162775. DOI: 10.1128/AAC.39.7.1526. View

18.

Hasek J, Svobodova J, STREIBLOVA E . Immunofluorescence of the microtubular skeleton in growing and drug-treated yeast protoplasts. Eur J Cell Biol. 1986; 41(2):150-6. View

19.

Woyke T, Pettit G, Winkelmann G, Pettit R . In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE. Antimicrob Agents Chemother. 2001; 45(12):3580-4. PMC: 90872. DOI: 10.1128/AAC.45.12.3580-3584.2001. View

20.

McCully E, Robinow C . Mitosis in heterobasidiomycetous yeasts. II. Rhodosporidium sp. (Rhodotorula glutinis) and Aessosporon salmonicolor (Sporobolomyces salmonicolor). J Cell Sci. 1972; 11(1):1-31. DOI: 10.1242/jcs.11.1.1. View